Herpes simplex vaccine - Agenus

Drug Profile

Herpes simplex vaccine - Agenus

Alternative Names: AG-707; HerpV; rhHSP70-PC

Latest Information Update: 26 Oct 2015

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Antigenics
  • Developer Agenus
  • Class Viral vaccines
  • Mechanism of Action CD4-positive T lymphocyte stimulants; CD8 positive T lymphocyte stimulants; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes - Herpes simplex virus infections

Highest Development Phases

  • Suspended Herpes simplex virus type 2 infections

Most Recent Events

  • 16 Mar 2015 Agenus has patent protection for HerpV vaccine in USA
  • 01 Jan 2015 Agenus completes a phase II trial in Herpes simplex virus infections (recurrent, adjunctive therapy) in USA (NCT01687595)
  • 26 Jun 2014 HerpV is available for licensing (\http://www.agenusbio.com/\)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top